Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

ALPHAMAB ONCOLOGY

康寧傑瑞生物製藥

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9966)

ANNOUNCEMENT IN RELATION TO DEALINGS IN SECURITIES OF A DIRECTOR DURING THE BLACK-OUT PERIOD

This announcement is made by Alphamab Oncology (the "**Company**") pursuant to paragraph D.15 of Appendix C3 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**").

The board (the "**Board**") of directors ("**Director(s)**") of the Company has been notified by Mr. CHO Man (左敏) ("**Mr. Cho**"), a non-executive Director, that on February 27, 2025, the spouse of Mr. Cho entered into an on-market transaction disposing of a total of 10,000 shares ("**Share(s)**") of the Company at a consideration of HK$6.15 per Share (the "**Transfer**") without first having notified the Company prior to the Transfer in accordance with the requirements stated in the paragraph B.8 of Appendix C3 to the Listing Rules.

As of the date of this announcement, Mr. Cho is deemed to be interested in 230,000 Shares by virtue of the interests held by his spouse and himself, representing approximately 0.02% of the total issued Shares (excluding treasury Shares).

Pursuant to paragraph A.3 of Appendix C3 to the Listing Rules, the Directors are prohibited from dealing in any securities of the Company on any day on which its financial results are published and during the period of 60 days immediately preceding the publication date of the annual results of the Company for the year ended December 31, 2024 (the "**Annual Results**"), as well as any period of delay in the publication of the Annual Results announcement (the "**Black-out Period**"). The Annual Results announcement was published on March 25, 2025, and the Transfer therefore fell within the Black-out Period and constituted a dealing of Shares by Mr. Cho and a non-compliance incident of paragraphs A.3 and B.8 of the Appendix C3 to the Listing Rules (the "**Non-compliance Incident**").

Mr. Cho reported the Non-compliance Incident to the Company and confirmed that the non-compliance was an inadvertent oversight, and he did not intend to commit such breach. Mr. Cho further confirmed that he does not possess any inside information of the Company when the Transfer took place, and he will apply closer scrutiny towards Appendix C3 of the Listing Rules.

Upon becoming aware of the Non-compliance Incident, the Company has reminded the Directors and senior management again of the requirements of the Appendix C3 to the Listing Rules and the importance of compliance with such provision. In order to ensure compliance with the Appendix C3 to the Listing Rules and prevent similar incidents in the future, the Company will provide regular training to the Directors, senior management and staff of the Company so as to keep them abreast of the relevant requirements. The Company will also circulate Appendix C3 to the Listing Rules and remind the Directors to compliance with its requirements in greater frequency to ensure compliance with and enhance their awareness of good corporate governance practices.

By order of the Board
Alphamab Oncology
Dr. XU Ting
Chairman and Executive Director

Hong Kong, September 19, 2025

As at the date of this announcement, the Board comprises Dr. XU Ting as the chairman of the Board and executive Director and Ms. LIU Yang as executive Director, Mr. CHO Man as non-executive Director, and Mr. WU Dong, Ms. WONG Yan Ki Angel and Dr. GAO Xiang as independent non-executive Directors.